WO2003048134A1 - Compose de triazole et son utilisation therapeutique - Google Patents
Compose de triazole et son utilisation therapeutique Download PDFInfo
- Publication number
- WO2003048134A1 WO2003048134A1 PCT/JP2002/012735 JP0212735W WO03048134A1 WO 2003048134 A1 WO2003048134 A1 WO 2003048134A1 JP 0212735 W JP0212735 W JP 0212735W WO 03048134 A1 WO03048134 A1 WO 03048134A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- haloalkyl
- alkyl
- triazole compound
- halogeno
- nitro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002354410A AU2002354410A1 (en) | 2001-12-05 | 2002-12-04 | Triazole compound and medicinal use thereof |
JP2003549326A JPWO2003048134A1 (ja) | 2001-12-05 | 2002-12-04 | トリアゾール化合物及びその医薬用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001/371687 | 2001-12-05 | ||
JP2001371687 | 2001-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003048134A1 true WO2003048134A1 (fr) | 2003-06-12 |
Family
ID=19180699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/012735 WO2003048134A1 (fr) | 2001-12-05 | 2002-12-04 | Compose de triazole et son utilisation therapeutique |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2003048134A1 (fr) |
AU (1) | AU2002354410A1 (fr) |
WO (1) | WO2003048134A1 (fr) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2862060A1 (fr) * | 2003-11-06 | 2005-05-13 | Galderma Res & Dev | Procede de synthese en phase solide de composes de types sulfures de diaryle. |
WO2007015809A2 (fr) * | 2005-07-22 | 2007-02-08 | Merck & Co., Inc. | Inhibiteurs de la transcriptase inverse du vih |
WO2011136269A1 (fr) | 2010-04-28 | 2011-11-03 | アステラス製薬株式会社 | Composé de tétrahydrobenzothiophène |
WO2013062065A1 (fr) | 2011-10-27 | 2013-05-02 | アステラス製薬株式会社 | Dérivé de n-thiényl benzamide substitué avec un aminoalkyle |
WO2014029983A1 (fr) | 2012-08-21 | 2014-02-27 | Ardelyx, Inc. | Composés et procédés d'inhibition d'un antiport à médiation par nhe dans le traitement de troubles associés à une rétention de fluide ou à une surcharge de sel et de troubles du tractus gastro-intestinal |
US8722695B2 (en) | 2009-12-11 | 2014-05-13 | Autifony Therapeutics Limited | Imidazolidinedione derivatives |
US9133175B2 (en) | 2010-12-06 | 2015-09-15 | Autifony Therapeutics Limited | Compounds |
US9193704B2 (en) | 2011-06-07 | 2015-11-24 | Autifony Therapeutics Limited | Hydantoin derivatives as KV3 inhibitors |
US9198923B2 (en) | 2009-01-26 | 2015-12-01 | Opko Ireland Global Holdings, Ltd. | Phosphate management with small molecules |
US9422252B2 (en) | 2012-05-22 | 2016-08-23 | Autifony Therapeutics Limited | Triazoles as Kv3 inhibitors |
US9669030B2 (en) | 2012-05-22 | 2017-06-06 | Autifony Therapeutics Limited | Hydantoin derivatives as Kv3 inhibitors |
WO2018129557A1 (fr) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Inhibiteurs d'antiport à médiation par nhe |
WO2018129552A1 (fr) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Composés utiles pour le traitement de troubles du tractus digestif |
WO2018129556A1 (fr) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Composés et procédés pour l'inhibition d'un antiport à médiation par échangeur sodium/proton (nhe) dans le traitement de troubles associés à une rétention d'eau ou à une surcharge en sel et de troubles du tractus gastro-intestinal |
EP3351248A1 (fr) | 2008-12-31 | 2018-07-25 | Ardelyx, Inc. | Composés et procédés d'inhibition d'un antiport à médiation par nhe dans le traitement de troubles associés à une rétention de fluide ou à une surcharge de sel et de troubles du tractus gastro-intestinal |
RU2662817C2 (ru) * | 2013-04-24 | 2018-07-31 | Дайити Санкио Компани, Лимитед | Соединение дикарбоновой кислоты |
US10272079B2 (en) | 2013-04-12 | 2019-04-30 | Ardelyx, Inc. | NHE3-binding compounds and methods for inhibiting phosphate transport |
US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
WO2023219127A1 (fr) * | 2022-05-11 | 2023-11-16 | 中外製薬株式会社 | Composition pharmaceutique pour le traitement ou la prévention d'une maladie kystique |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3769411A (en) * | 1968-09-04 | 1973-10-30 | Rohm & Haas | Fungicidal 1,2,4-4h-triazole derivatives |
US4372953A (en) * | 1980-02-29 | 1983-02-08 | Otsuka Pharmaceutical Company, Limited | Tetrazole derivatives, and anti-ulcer composition containing the same |
US4820625A (en) * | 1986-09-19 | 1989-04-11 | Fuji Photo Film Co., Ltd. | Direct positive silver halide photographic material |
WO1999002503A1 (fr) * | 1997-07-07 | 1999-01-21 | Basf Aktiengesellschaft | Composes de triazole et leur utilisation comme ligands de la dopamine d¿3? |
-
2002
- 2002-12-04 JP JP2003549326A patent/JPWO2003048134A1/ja active Pending
- 2002-12-04 WO PCT/JP2002/012735 patent/WO2003048134A1/fr active Application Filing
- 2002-12-04 AU AU2002354410A patent/AU2002354410A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3769411A (en) * | 1968-09-04 | 1973-10-30 | Rohm & Haas | Fungicidal 1,2,4-4h-triazole derivatives |
US4372953A (en) * | 1980-02-29 | 1983-02-08 | Otsuka Pharmaceutical Company, Limited | Tetrazole derivatives, and anti-ulcer composition containing the same |
US4820625A (en) * | 1986-09-19 | 1989-04-11 | Fuji Photo Film Co., Ltd. | Direct positive silver halide photographic material |
WO1999002503A1 (fr) * | 1997-07-07 | 1999-01-21 | Basf Aktiengesellschaft | Composes de triazole et leur utilisation comme ligands de la dopamine d¿3? |
Cited By (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2862060A1 (fr) * | 2003-11-06 | 2005-05-13 | Galderma Res & Dev | Procede de synthese en phase solide de composes de types sulfures de diaryle. |
WO2005047237A1 (fr) * | 2003-11-06 | 2005-05-26 | Galderma Research & Development, S.N.C. | Procede de synthese en phase solide de composes de types sulfures de diaryle |
WO2007015809A2 (fr) * | 2005-07-22 | 2007-02-08 | Merck & Co., Inc. | Inhibiteurs de la transcriptase inverse du vih |
WO2007015809A3 (fr) * | 2005-07-22 | 2007-03-29 | Merck & Co Inc | Inhibiteurs de la transcriptase inverse du vih |
US7807684B2 (en) | 2005-07-22 | 2010-10-05 | Merck Sharp & Dohme Corp. | HIV reverse transcriptase inhibitors |
EP3939964A1 (fr) | 2008-12-31 | 2022-01-19 | Ardelyx, Inc. | Combinaisons d'inhibition d'un antiport a mediation par nhe dans le traitement de troubles associes a une retention de fluide ou a une surcharge de sel et de troubles du tractus gastro-intestinal |
EP3351248A1 (fr) | 2008-12-31 | 2018-07-25 | Ardelyx, Inc. | Composés et procédés d'inhibition d'un antiport à médiation par nhe dans le traitement de troubles associés à une rétention de fluide ou à une surcharge de sel et de troubles du tractus gastro-intestinal |
US9198923B2 (en) | 2009-01-26 | 2015-12-01 | Opko Ireland Global Holdings, Ltd. | Phosphate management with small molecules |
US10632118B2 (en) | 2009-12-11 | 2020-04-28 | Autifony Therapeutics Limited | Imidazolidinedione derivatives |
US9849131B2 (en) | 2009-12-11 | 2017-12-26 | Autifony Therapeutics Limited | Imidazolidinedione derivatives |
US8722695B2 (en) | 2009-12-11 | 2014-05-13 | Autifony Therapeutics Limited | Imidazolidinedione derivatives |
US10058551B2 (en) | 2009-12-11 | 2018-08-28 | Autifony Therapeutics Limited | Imidazolidinedione derivatives |
US9216967B2 (en) | 2009-12-11 | 2015-12-22 | Autifony Therapeutics Limited | Imidazolidinedione derivatives |
US8729068B2 (en) | 2010-04-28 | 2014-05-20 | Astellas Pharma Inc. | Tetrahydrobenzothiophene compound |
KR20130073908A (ko) | 2010-04-28 | 2013-07-03 | 아스텔라스세이야쿠 가부시키가이샤 | 테트라하이드로벤조티오펜 화합물 |
JP5617919B2 (ja) * | 2010-04-28 | 2014-11-05 | アステラス製薬株式会社 | テトラヒドロベンゾチオフェン化合物 |
CN102869656A (zh) * | 2010-04-28 | 2013-01-09 | 安斯泰来制药株式会社 | 四氢苯并噻吩化合物 |
EA022521B1 (ru) * | 2010-04-28 | 2016-01-29 | Астеллас Фарма Инк. | Соединения тетрагидробензотиофена, фармацевтическая композиция на их основе, их применение и способ лечения гиперфосфатемии |
US9284295B2 (en) | 2010-04-28 | 2016-03-15 | Astellas Pharma Inc. | Tetrahydrobenzothiophene compound |
WO2011136269A1 (fr) | 2010-04-28 | 2011-11-03 | アステラス製薬株式会社 | Composé de tétrahydrobenzothiophène |
US9133175B2 (en) | 2010-12-06 | 2015-09-15 | Autifony Therapeutics Limited | Compounds |
US9346790B2 (en) | 2010-12-06 | 2016-05-24 | Autifony Therapeutics Limited | Hydantoin derivatives useful as Kv3 inhibitors |
US10835534B2 (en) | 2010-12-06 | 2020-11-17 | Autifony Therapeutics Limited | Compounds |
US9422272B2 (en) | 2010-12-06 | 2016-08-23 | Autifony Therapeutics Limited | Compounds |
US11197859B2 (en) | 2010-12-06 | 2021-12-14 | Autifony Therapeutics Limited | Hydantoin derivatives useful as Kv3 inhibitors |
US9833452B2 (en) | 2010-12-06 | 2017-12-05 | Autifony Therapeutics Limited | Compounds |
US11541052B2 (en) | 2010-12-06 | 2023-01-03 | Autifony Therapeutics Limited | Compounds |
US10555945B2 (en) | 2010-12-06 | 2020-02-11 | Autifony Therapeutics Limited | Compounds |
US10265316B2 (en) | 2010-12-06 | 2019-04-23 | Autifony Therapeuctics Limited | Hydantoin derivatives useful as Kv3 inhibitors |
US10098881B2 (en) | 2010-12-06 | 2018-10-16 | Autifony Therapeutics Limited | Compounds |
US11583527B2 (en) | 2010-12-06 | 2023-02-21 | Autifony Therapeutics Limited | Hydantoin derivatives useful as Kv3 inhibitors |
US9193704B2 (en) | 2011-06-07 | 2015-11-24 | Autifony Therapeutics Limited | Hydantoin derivatives as KV3 inhibitors |
KR20140096322A (ko) | 2011-10-27 | 2014-08-05 | 아스텔라스세이야쿠 가부시키가이샤 | 아미노 알킬 치환 n-티에닐벤즈아미드 유도체 |
US9062032B2 (en) | 2011-10-27 | 2015-06-23 | Astellas Pharma Inc. | Aminoalkyl-substituted N-thienylbenzamide derivative |
WO2013062065A1 (fr) | 2011-10-27 | 2013-05-02 | アステラス製薬株式会社 | Dérivé de n-thiényl benzamide substitué avec un aminoalkyle |
JPWO2013062065A1 (ja) * | 2011-10-27 | 2015-04-02 | アステラス製薬株式会社 | アミノアルキル置換n−チエニルベンズアミド誘導体 |
US11180461B2 (en) | 2012-05-22 | 2021-11-23 | Autifony Therapeutics Limited | Triazoles as Kv3 inhibitors |
US10160730B2 (en) | 2012-05-22 | 2018-12-25 | Autifony Therapeutics Limited | Triazoles as KV3 inhibitors |
US10611735B2 (en) | 2012-05-22 | 2020-04-07 | Autifony Therapeutics Limited | Triazoles as Kv3 inhibitors |
US9669030B2 (en) | 2012-05-22 | 2017-06-06 | Autifony Therapeutics Limited | Hydantoin derivatives as Kv3 inhibitors |
US9422252B2 (en) | 2012-05-22 | 2016-08-23 | Autifony Therapeutics Limited | Triazoles as Kv3 inhibitors |
US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
WO2014029983A1 (fr) | 2012-08-21 | 2014-02-27 | Ardelyx, Inc. | Composés et procédés d'inhibition d'un antiport à médiation par nhe dans le traitement de troubles associés à une rétention de fluide ou à une surcharge de sel et de troubles du tractus gastro-intestinal |
US10940146B2 (en) | 2013-04-12 | 2021-03-09 | Ardelyx, Inc. | NHE3-binding compounds and methods for inhibiting phosphate transport |
US10272079B2 (en) | 2013-04-12 | 2019-04-30 | Ardelyx, Inc. | NHE3-binding compounds and methods for inhibiting phosphate transport |
RU2662817C2 (ru) * | 2013-04-24 | 2018-07-31 | Дайити Санкио Компани, Лимитед | Соединение дикарбоновой кислоты |
US11147884B2 (en) | 2017-01-09 | 2021-10-19 | Ardelyx, Inc. | Inhibitors of NHE-mediated antiport |
WO2018129552A1 (fr) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Composés utiles pour le traitement de troubles du tractus digestif |
US11242337B2 (en) | 2017-01-09 | 2022-02-08 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
WO2018129557A1 (fr) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Inhibiteurs d'antiport à médiation par nhe |
WO2018129556A1 (fr) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Composés et procédés pour l'inhibition d'un antiport à médiation par échangeur sodium/proton (nhe) dans le traitement de troubles associés à une rétention d'eau ou à une surcharge en sel et de troubles du tractus gastro-intestinal |
WO2023219127A1 (fr) * | 2022-05-11 | 2023-11-16 | 中外製薬株式会社 | Composition pharmaceutique pour le traitement ou la prévention d'une maladie kystique |
Also Published As
Publication number | Publication date |
---|---|
AU2002354410A1 (en) | 2003-06-17 |
JPWO2003048134A1 (ja) | 2005-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003048134A1 (fr) | Compose de triazole et son utilisation therapeutique | |
TW200500362A (en) | 5-membered heteroaromatic ring compound and pharmaceutical use thereof | |
EP1156045A4 (fr) | Derives d'amides et compositions de medicaments | |
EP1939175A4 (fr) | Dérivé sulfonamide ayant une activité antagoniste de récepteur pgd2 | |
WO2001009103A3 (fr) | Agents antiproliferatifs imidazole | |
CA2534024A1 (fr) | Nouveaux composes possedant une activite inhibitrice dirigee contre le transporteur dependant du sodium | |
WO2005097129A3 (fr) | Compose de 6-azaindole | |
WO2002057252A3 (fr) | Inhibiteurs sulfonamides heterocycliques de la production de beta-amyloide | |
WO2007071632A3 (fr) | Derives de pyridinyl-quinazoline et leur utilisation medicale | |
GEP20063890B (en) | Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | |
EA200300695A1 (ru) | Ингибитор высвобождения воспалительного цитокина | |
EP1396493A4 (fr) | Composes heterocycliques | |
TNSN03045A1 (fr) | Quinazolines as mmp-13 inhibitors | |
EP1072263A4 (fr) | Derives d'amide et antagonistes de nociceptine | |
WO2005092858A3 (fr) | Composes alpha-aryle ou heteroaryle methyle beta piperidino propanamide en tant qu'antagoniste du recepteur orl1 | |
WO2005095395A3 (fr) | Derives de tetrahydronaphtyridine et procede d’elaboration desdits derives | |
WO2005012269A8 (fr) | Nouveau compose azole | |
PT892793E (pt) | Derivados 2-cianoiminoimidazolo inibidores da pde iv | |
CA2384354A1 (fr) | Derives de pyrimidine et herbicides les contenant | |
EP1243268A4 (fr) | Composition medicinale | |
CA2383583A1 (fr) | Derive de benzopyran | |
WO2001003685A3 (fr) | Nouveaux promedicaments pour amidines antimicrobiennes | |
WO2002062767A1 (fr) | Nouveaux derives de quinazoline | |
EP1491190A4 (fr) | Inhibiteur de decomposition pour matrice extracellulaire de cartilage | |
WO2003035610A1 (fr) | Derive de sulfonamide a effet inhibiteur sur les mmp |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AU AZ BA BB BR BY BZ CA CN CO CR CU DM DZ EC GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LV MA MD MG MK MN MX NO NZ OM PH PL RO RU SC SG TJ TM TN TT UA US UZ VC VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003549326 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |